News
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
The National Institutes of Health has launched a five-year, $215 million public-private partnership (PPP) with biopharma industry to accelerate development of immunotherapies targeted at cancer treatment. This initiative, called The Partnership for Accelerating Cancer Therapies (PACT) will be
Researchers at the NIH have been not only at the forefront of developing an anti-HIV drug, but also managed to create a groundswell for such work though partnering with industry. This is because very few companies can fund early-stage research. Joe Allen of IPWatchdog.com wrote in his blog post
The Office of Intramural Research, Office of the Director, NIH, invites you to the twelfth annual Philip S. Chen, Jr., Ph.D. Distinguished Lecture on Innovation and Technology Transfer. The lecture will be held on November 17, 2017 at 10:00AM in the Masur Auditorium, Building 10, NIH campus in